Futility analysis augurs defeat in pivotal trial testing of NuCana's lead drug in metastatic pancreatic cancer

Nearly two years after making its public debut, UK-based NuCana’s mission to make chemotherapies more potent and safer was dealt a blow, after a pivotal study testing its lead experimental drug halted enrollment in a hard-to-treat advanced form of cancer, following a futility analysis.